Expression of Killer Immunoglobulin Receptor Genes among HIV-Infected Individuals with Non-AIDS Comorbidities

Table 5

Observed frequency of KIR expression among HIV-infected individuals with and without comorbid conditions.

	With diabetes ()	Without diabetes ()	value	With hyperlipidemia ()	Without hyperlipidemia ()	value	With CVD ()	Without CVD ()	value	With hypertension ()	Without hypertension ()	value
KIR genes
KIR2DL1	9 (25%)	27 (75%)	1	29 (39.7%)	44 (60.3%)	0.563	8 (8.3%)	89 (91.7%)	0.074	27 (45%)	33 (55%)	0.184
KIR2DL2	5 (25%)	15 (75%)	1	14 (35%)	26 (65%)	0.352	5 (9.4%)	48 (90.6%)	1	17 (53.1%)	15 (46.9%)	0.46
KIR2DL3	9 (26.5%)	25 (73.5%)	0.562	28 (41.2%)	40 (58.8%)	1	8 (8.8%)	83 (91.2%)	0.294	25 (43.1%)	33 (56.9%)	0.047
KIR2DL5	7 (28%)	18 (72%)	0.687	20 (39.2%)	31 (60.8%)	0.805	5 (7.7%)	60 (92.3%)	0.49	21 (48.8%)	22 (51.2%)	1
KIR2DP1	9 (25%)	27 (75%)	1	29 (39.7%)	44 (60.3%)	0.563	8 (8.3%)	89 (91.7%)	0.074	27 (45%)	33 (55%)	0.184
KIR2DS1	6 (31.6%)	13 (68.4%)	0.447	16 (42.1%)	22 (57.9%)	1	4 (8.9%)	41 (91.1%)	1	17 (53.1%)	15 (46.9%)	0.46
KIR2DS2	5 (25%)	15 (75%)	1	14 (35%)	26 (65%)	0.352	5 (9.4%)	48 (90.6%)	1	17 (53.1%)	15 (46.9%)	0.46
KIR2DS3	4 (33.3%)	8 (66.7%)	0.432	11 (42.3%)	15 (57.7%)	1	1 (2.9%)	33 (97.1%)	0.159	11 (55%)	9 (45%)	0.591
KIR2DS4	6 (18.2%)	27 (81.8%)	0.038	26 (38.2%)	42 (61.8%)	0.259	10 (10.9%)	82 (89.1%)	0.592	26 (45.6%)	31 (54.4%)	0.463
KIR2DS5	6 (33.3%)	12 (66.7%)	0.269	13 (39.4%)	20 (60.6%)	1	4 (10%)	36 (90%)	1	15 (51.7%)	14 (48.3%)	0.622
KIR3DL1	6 (18.2%)	27 (81.8%)	0.038	26 (38.2%)	42 (61.8%)	0.259	10 (10.9%)	82 (89.1%)	0.592	26 (45.6%)	31 (54.4%)	0.463
KIR3DS1	6 (35.3%)	11 (64.7%)	0.251	16 (44.4%)	20 (55.6%)	0.642	3 (6.8%)	41 (93.2%)	0.508	16 (55.2%)	13 (44.8%)	0.324
KIR haplotypes
AA	1 (10%)	9 (90%)	0.393	8 (47.1%)	9 (52.9%)	0.585	3 (11.1%)	24 (88.9%)	0.722	7 (39%)	11 (61%)	0.418
Bx	8 (29.6%)	19 (70.4)		23 (39%)	36 (61%)		7 (9.3%)	68 (90.2%)		24 (51.1%)	23 (48.9%)

CVD: cardiovascular disease. Significant values () of Fisher’s exact test are indicated by () and italic font.